But we do have another item this afternoon, which is the short debate, which is now to be presented.

If Members could leave the Chamber quietly, I'll call Russell George to introduce his short debate. 

Diolch, Llywydd. I give a minute of my time to Mike Hedges and Rhun ap Iorwerth as well. We currently face extreme pressures on our NHS, our health, and our economy, and our response to this extreme pressure must also provide long-term solutions that improve the lives of people in Wales.

Along with myself as chair, David Rees, Altaf Hussain, Jayne Bryant, Mike Hedges and Sioned Williams are all Members of the cross-party group on medical research. We launched an inquiry back in 2021 to establish the benefits of medical research to Wales. The cross-party group is due to publish its report this autumn, but our findings up until now outline the very real and tangible short-, medium- and long-term benefits of a thriving medical research environment. This view is supported by the people of Wales. According to the British Heart Foundation Cymru, an overwhelming majority of 82 per cent of the people of Wales believe that it is important for medical research to happen here.

So far, we've taken evidence from clinicians, patients, economists, researchers, funders and industry and we've heard unequivocally that medical research has enormous benefits for the Welsh economy, Welsh patients and the Welsh NHS. On the economic benefits, the cross-party group heard evidence from the Fraser of Allander Institute at the University of Strathclyde and the British Heart Foundation Cymru. Both contributions provided significant evidence that medical research is a vital part of the Welsh economy. Those recipients of research funding purchase goods and services in order to undertake the research and this generates activity in the supply chain and across the whole of the Welsh economy.

Medical research can boost output and productivity in the economy, with new technologies, medicines and processes, and as new methods and technologies are discovered, there are knowledge spillovers into the public, private and third sectors, which further boosts productivity and the economic growth. Economic modelling commissioned by the British Heart Foundation shows that charity-funded medical research alone supports £86 million in output and £55 million in gross value added, and 950 full-time equivalent Welsh jobs. Most of these 950 jobs are high quality and high-paid roles. The Association of the British Pharmaceutical Industry stressed to the cross-party group that increasing investment in science will help provide high-quality jobs that would drive the future of the Welsh economy.

Taking evidence from patients, clinicians and researchers, the cross-party group has seen first-hand the huge benefits that medical research can provide to patients. Breakthroughs in medical research generate improvements in preventing, diagnosing and treating conditions, improving patient experience, quality of life, and medical outcomes. Patients in Wales benefit every day from medical breakthroughs that happen all round the world, but there is also a huge benefit to patients if medical research happens right here in Wales. The cross-party group heard that patients who participate in clinical trials receive the best standard of care, and because of strict regulations in clinical trials, these patients are more likely to have a better experience, better treatment and better outcomes than patients who do not participate in clinical trials. For example, in motor neurone disease, there are UK-wide developments, and the Welsh Government, I think, must make sure that patients in Wales have access to those clinical trials.

Patients and clinicians also highlighted evidence to the cross-party group that patients who attend a hospital with a positive research environment have a better outcome. There may be many reasons, of course, for this, but the cross-party group has considered that research-active hospitals may have greater knowledge and more developed infrastructure. Research-active hospitals may find it easier to implement evidence-based practice and innovative procedures, and this culture of innovation may also enable research-active hospitals to implement and follow up-to-date clinical guidance, providing the very best care for patients.

This capacity for change and innovation is absolutely crucial if our NHS is to recover from the extreme pressures felt across the service currently. Medical research provides endless opportunities for cost savings in the NHS, as well as driving innovation and streamlining practices. The cross-party group heard from the pharmaceutical industry that each patient participating in a clinical trial represents a £9,000 saving to the NHS. That's £9,000 per patient. I can see the Minister looking at that with perhaps a smile on her face.

But one of the biggest problems facing our NHS is, of course, the recruitment, retention and support of NHS staff. The cross-party group has seen evidence that a thriving medical research environment is absolutely crucial to any workforce planning. From an evidence session with the Royal College of Physicians and clinicians, the cross-party group heard that that the opportunity to engage in medical research is important to clinicians' careers. Clinicians reported that engaging in medical research supports their career development, their morale and, therefore, their ability to care for their patients. Providing this opportunity to clinicians would not only support staff retention, but might even improve recruitment, by making the Welsh NHS a more attractive place to work, and this would bring more expertise into Wales and start to fill crucial vacancies across the health service. The Royal College of Nursing found that in Wales there were two and a half times as many applications per post when an academic component was advertised with the role.

A report commissioned by the Association of the British Pharmaceutical Industry shows huge benefits that could be released across the UK and Wales if life sciences visions were fully implemented. According to the report, the NHS would generate an additional £165 million in revenue and £32 million in cost savings per year if recruitment to UK industry trials rose on a par with Spain, for example. The UK would generate £68 billion in additional GDP over the next 30 years if the UK pharmaceutical industry's spending on research and development rose on a par with the US. I accept that the Welsh Government has consulted on its draft innovation strategy, but this must be backed up by capital and ambitious leadership if we're to really feel the benefits of medical research.

My thanks to the many organisations who helped in terms of contributing to this short debate today, and particularly to the British Heart Foundation Cymru and Gemma Roberts. Thank you very much. Diolch yn fawr.

The Deputy Presiding Officer took the Chair.

Can I thank Russ George for giving me a minute in this debate, but, more importantly, thank him for bringing this debate into the Chamber and putting forward a lot of ideas that I fully support? I want to continue the point made by Russ on the economic importance of medical research. Medical research has the advantage of being able to be carried out anywhere; you do not have to be in London and the south-east, you can be anywhere. It benefits from university involvement, and we are fortunate in Wales to have excellent universities. We need to support medical research at our universities and benefit from what they produce.

A major growth area in the world economy is life science. This has got to be a priority. It's meant to be a priority of the Welsh Government's, but it really does have to play a more important part. Universities can play a key role in developing further the Welsh life science industry. Unlike other parts of the UK, the activity and investment isn't concentrated in just one wealthy area or region. The growth of the life science sector in Wales spans the length and breadth of the country, from harvesting jellyfish collagen in the west to the foundation of cutting-edge infantile prosthetics in the north. It really is important that we make the most of it.

May I thank Russell George for bringing forward this short debate at the Senedd today? I just want to echo the comments that have been made already about the benefit that can come to us in so many ways in developing medical trials in Wales. The benefits come to patients, clearly, because the closer patients are to where trials are taking place the greater the chance that they can become part of those trials, and there are clear opportunities in terms of health that emanate from that. It is a way of strengthening our workforce. People want to work where the most innovative work is being done, be that research staff, scientific staff and clinical staff too. There are clear economic benefits in developing the life sciences sector, which has firm foundations in Wales but has significant room for growth. Tying the industry, with that commercial element, with the need to promote research within our universities is something that I hope that we can all, as Members of the Senedd here, be supportive of. Once again, I'm very grateful that this issue has been raised before us today.

I call on the Minister for Health and Social Services to reply to the debate—Eluned Morgan.

Thank you very much. First of all, I want to thank Russell George for bringing this important issue to the Chamber.

The medical research landscape is broad, from funding pre-clinical laboratory research to the more applied clinical research that takes place in the NHS. My responsibilities are focused on more applied medical research, which I think makes a vital contribution to treatment, development and evaluation, service organisation and delivery, and, crucially, outcomes for patients. I'm aware of the work of the cross-party group on medical research, which I know, Russell, you chair, and I'm looking forward very much to seeing your new report, because I know that the recommendations in previous reports have been very useful to us. 

As Minister for Health and Social Services, the funding I provide through Health and Care Research Wales makes a huge difference to the medical research landscape. I'm pleased to say that, last year, I agreed an additional recurring £5 million increase to the Health and Care Research Wales budget. This will be used to support the implementation of the Wales cancer research strategy, to create a new adult social care research centre, and to fund an evidence centre that will identify and answer questions of urgent importance to policy and practice. It will also be used to offer new personal award schemes to support capacity building in the NHS and social care sectors, which will enhance our commissioned research programme and support new models for clinical research delivery. This new investment complements the £42 million we spend annually on our Wales-wide health and care research infrastructure, which includes funding for the NHS research workforce, our research centres and units, our research funding schemes, and our partnership working.

But everyone understands the challenges of the current financial environment. I'm afraid that the situation is being exacerbated by the UK Government's approach to the UK shared prosperity fund, which replaces EU funding, which means Wales as a whole is worse off, coupled of course with the uncertainty over future access to the EU funding programme Horizon Europe. I am concerned that delays in associating with the Horizon programme, if we ever do so, are also compromising our international research collaborations on medical research. In many ways, the financial climate underlines the importance of collaboration. 

We do collaborate and have partnerships with many organisations. For example, we're a part of the Medical Research Council-administered Health Data Research UK initative, and the UK Prevention Research Partnership, all of which are cross-fund alliances. We co-fund the Cardiff Experimental Cancer Medicine Centre with Cancer Research UK, which enables patient access to early stage clinical trials, and translation of scientific discoveries into new cancer treatments. We have active partnerships that fund specific research programmes with the Scar Free Foundation and Fight for Sight. We participate in a range of UK research funding programmes run by the National Institute for Health and Care Research in England, which provides Welsh researchers with access to large multimillion-pound funding streams across the health research spectrum.

We can't, however, achieve success without having a nurturing research environment for health and social care professionals. Staff who are evidence driven are more likely to use innovation and improvement to develop ways of working that drive change, transformation and patient benefit. Research careers are therefore highly rewarding, and organisations that are research-active have a stronger ability to attract the best staff and retain them. And that's why, last year, Health and Care Research Wales, Social Care Wales and Health Education and Improvement Wales initiated a joint review of research career and training pathways, which set out recommendations in the 'Making research careers work: a review of career pathways in health and social care' report. 

We have right here in Wales new treatment options through participation in research, which can be especially important for conditions where all other options have been exhausted. There are over 500 studies taking place in the Welsh NHS that are currently accessible to our population, covering conditions such as motor neurone disease, long COVID, asthma, cancer and diabetes. We're also seeing huge advancements in areas such as genomics, brain imaging and advanced therapies, which are key to discovering future treatments. But we all recognise that NHS services are under unprecedented pressures and undertaking research is challenging. We've seen the impact of the pandemic, coupled with workforce pressures, having a real effect on the research capacity in the NHS. Investing in our dedicated research delivery workforce and awarding NHS research time awards through the faculty has, therefore, never been more important. 

Later this spring, a refreshed NHS research and development framework, which has been co-produced with the NHS, will be published, outlining what a high-performing, research-active NHS organisation looks like, and we also need to capitalise on our strengths in health data, creating a new digital infrastructure, to make study delivery faster and more efficient.

Before I sum up, I want to focus on the real difference that research can make to the lives of people, patients and communities. We've seen, particularly at the height of the pandemic, how crucial good research is in helping to deliver patient care, treatment and, of course, vaccines. Wales is leading in areas of research development, which has a real impact not only on Welsh patients, but across the UK. 

One of the main diseases affecting people in Wales, namely cancer, has also had key research success. Our researchers recruited over 1,000 volunteers to the SYMPLIFY process, which was a crucial, new early identification test for multiple cancers, which can identify over 50 cancers. In addition, the FAKTION clinical trial on breast cancer, which is also Welsh-based, has also had success in slowing the growth of tumours and extending patient life. 

Finally, I want to mention that strong public involvement in research, design and delivery improves the quality and relevance of research, helping to ensure that research delivers public benefit and addresses public need, and this is something that I know is at the heart of Health and Care Research Wales activities. Diolch yn fawr. 

Thank you very much, everyone. That brings today's proceedings to a close. 

The meeting ended at 18:48.